Digital therapeutics (DTx) were gaining popularity as tools to help slash the US’ $3 trillion annual spending on chronic disease, and the pandemic has vaulted digital therapies into the spotlight. Now, the Teladoc-Livongo megamerger is heating up competition in the DTx space as players race to capture a slice of a market slated to reach $56 billion by 2025.
Voice-activated technology is in the early stages of development, but it has the potential to change the way healthcare brands, providers and patients interact—eventually making the healthcare system more efficient and effective.